PETQ:NSD-PetIQ, Inc (USD)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | NSD

Last Closing Price

USD 29.51

Change

-0.96 (-3.15)%

Market Cap

USD 0.87B

Volume

0.36M

Average Target Price

USD 41.00 (+38.94%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

PetIQ, Inc. operates as a pet medication and wellness company. It operates through two segments, Products and Services. The company offers prescription pet medications, including products for arthritis, thyroid, and diabetes and pain treatments, as well as heartworm preventatives, antibiotics, and other specialty medications; and over-the-counter medications and supplies, such as flea and tick control products in various forms comprising spot on treatments, chewables, and collars. It also provides health and wellness products that include dental treats and nutritional supplements, which comprise hip and joint, vitamins, and skin and coat products The company offers its products primarily under the PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Advecta, SENTRY, Sergeants, PetLock, Heart Shield Plus, TruProfen, Betsy Farms, PetAction, Minties, Vera, and Delightibles brands. In addition, the company offers a suite of services at community clinics and wellness centers hosted at pet retailers across 41 states, including diagnostic tests, vaccinations, prescription medications, microchipping, and wellness checks. As of March 10, 2020, it operated through approximately 60,000 points of distribution across retail and e-commerce channels. The company was founded in 2010 and is headquartered in Eagle, Idaho.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-10-26 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MYL Mylan N.V

-0.64 (-4.08%)

USD8.11B 29.43 7.35
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
PCRX Pacira BioSciences, Inc

-1.65 (-2.97%)

USD2.37B 870.20 69.93
CRON Cronos Group Inc

-0.30 (-5.15%)

USD2.03B 2.89 N/A
IRWD Ironwood Pharmaceuticals, Inc

-0.07 (-0.73%)

USD1.54B 15.31 12.76
ENDP Endo International plc

-0.24 (-4.15%)

USD1.33B N/A 8.81
APHA Aphria Inc

+0.02 (+0.44%)

USD1.31B 57.50 454.68
ATNX Athenex, Inc

+0.23 (+2.01%)

USD1.07B N/A N/A
SUPN Supernus Pharmaceuticals, Inc

-0.39 (-1.94%)

USD1.06B 9.15 5.82
AMPH Amphastar Pharmaceuticals, Inc

-0.55 (-2.64%)

USD0.99B 260.50 31.99

ETFs Containing PETQ

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 17.80% 88% B+ 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.80% 88% B+ 73% C
Trailing 12 Months  
Capital Gain 17.10% 79% C+ 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.10% 79% C+ 67% D+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 8.44% N/A N/A 62% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.44% N/A N/A 58% F
Risk Return Profile  
Volatility (Standard Deviation) 22.09% N/A N/A 65% D
Risk Adjusted Return 38.19% N/A N/A 60% D-
Market Capitalization 0.87B 83% B 67% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 134.36 17% F 9% F
Price/Book Ratio 2.70 54% F 45% F
Price / Cash Flow Ratio 41.79 5% F 8% F
EV/EBITDA 110.52 15% F 7% F
Management Effectiveness  
Return on Equity -7.74% 76% C 44% F
Return on Invested Capital 1.66% 81% B- 49% F
Return on Assets 1.58% 81% B- 65% D
Debt to Equity Ratio 88.79% 29% F 26% F
Technical Ratios  
Short Ratio 18.85 7% F 2% F
Short Percent 28.98% 6% F 7% F
Beta 1.56 39% F 27% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.